135.34 0.00 (0.00%)
After hours: 4:45PM EDT
|Bid||134.00 x 800|
|Ask||135.49 x 1200|
|Day's Range||133.65 - 138.63|
|52 Week Range||32.80 - 176.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 17, 2018 - Jul 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||190.47|
While pharmaceutical companies often make it into such lists, the inclusion of a body-cam business and a small e-commerce player may surprise you.
As we’ve discussed, analysts expect Sarepta Therapeutics’ (SRPT) revenue to grow 93.6% year-over-year in Q2 2108, to $67.8 million from $35.0 million. The chart below shows analysts’ recommendations over the last 12 months.
Short interest is moderately high for SRPT with between 10 and 15% of shares outstanding currently on loan. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $2.04 billion.
Analysts expect Sarepta Therapeutics’ (SRPT) revenue to rise ~93.6% to $67.8 million in Q2 2018 due to sales of Exondys 51, the company’s only commercialized drug. The chart below details Sarepta’s product portfolio.
Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA1-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. Sarepta is expected to release its Q2 2018 earnings on July 18. The chart below shows Sarepta’s revenue and EPS since Q1 2017, and estimates for Q2 2018.
Gene therapy companies are looking to advance the technology, creating potentially curative treatments for genetic diseases.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
On July 6, Gemphire Therapeutics (GEMP) stock closed at $8.09, ~70% higher than its 52-week low of $4.75 on May 7. After Gemphire announced positive clinical trial results on June 28, its stock price started to rise and closed at $5.24, and on June 29, it rose ~94.47% to $10.19.
The Food and Drug Administration’s approval of Sarepta Therapeutic’s Duchenne drug is a teachable moment for 21st-century regulatory science (“A Risky Drug Approval Lesson”, Review and Outlook, July 5). The FDA cannot regulate drug trials properly without factoring in patients’ opinions. Is that calculation reproducible across therapeutic categories? istock/getty images View of human skeletal muscle under a microscope.
Full details of the study will be announced at the Alzheimer's Association International Conference (AAIC) on July 22-26 or possibly at a later conference in October. which gapped up big on news in mid-June.
In the week that ended on June 29, Vertex Pharmaceuticals (VRTX) stock closed at $169.96, which represented a ~7% rise from its previous week’s close of $159.76. On June 29, Vertex Pharmaceuticals’ stock price rose 15.16% to reach $169.96 from its previous day’s close of $147.59. In June, Vertex Pharmaceuticals announced that its cystic fibrosis drug Orkambi would be reimbursed in Sweden.
Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.
Short interest is moderate for SRPT with between 5 and 10% of shares outstanding currently on loan. The net inflows of $3.54 billion over the last one-month into ETFs that hold SRPT are not among the highest of the last year and have been slowing.
Some welcome news arrived recently for boys with a condition called Duchenne muscular dystrophy. A new therapy is showing promising results, and it raises a question for the Food and Drug Administration: What if society had missed this moment? In late June Sarepta Therapeutics, a biotech company, released data on a gene therapy for Duchenne, a disease that weakens muscles and organ function.
Three business that offer practical investment opportunities whether cryptocurrencies form a speculative bubble again or not.
So far the holiday trading party isn't too exciting. The indices are green and breadth is quite strong with about 4450 gainers to just 1800 losers but the pockets of momentum are limited and the FAANG names aren't participating.
Sarepta Therapeutics, Inc. (SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted equity awards on June 29, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to twenty individuals hired by Sarepta in June 2018. The employees received, in the aggregate, options to purchase 84,620 shares of Sarepta's common stock.
LONDON, UK / ACCESSWIRE / June 29, 2018 / If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories.
On June 27, Summit Therapeutics (SMMT) announced that its phase two PhaseOut DMD trial evaluating investigational utrophin modulator ezutromid in the Duchenne muscular dystrophy (or DMD) indication failed to meet its primary endpoint. This news also affected the stock prices of Sarepta Therapeutics (SRPT), which dropped 4.6% and reached $129.3 on June 27. In the absence of the DMD program, Summit Therapeutics is heavily dependent on the success of its late-stage investigational precision antibiotic, ridinilazole, which is being developed as a front-line therapy for patients suffering from clostridium difficile infections.
The Street grew more bullish on Solid Biosciences Inc (NASDAQ: SLDB ) last week following progress announcements on Solid and peer candidates. At least three analysts raised their valuation targets: The ...